Back to top

genomics: Archive

Zacks Equity Research

REGN Signs $256M Buyout Deal With 23andMe to Boost Genomics Research

Regeneron is set to acquire 23andMe assets for $256 million to boost genetic drug discovery. The transaction is expected to close by third-quarter 2025.

REGNPositive Net Change BAYRYPositive Net Change HALOPositive Net Change ALLOPositive Net Change

Ekta Bagri

Promising Genomics & Synthetic Biology Stocks to Consider in 2025

Investors interested in the Genomics and Synthetic Biology theme should consider these stocks: Twist Bioscience Corporation, Wave Life Sciences, and CRISPR Therapeutics AG.

ILMNPositive Net Change BEAMPositive Net Change WVEPositive Net Change NTLAPositive Net Change CRSPPositive Net Change TWSTPositive Net Change